@article{oai:nagasaki-u.repo.nii.ac.jp:00015296,
 author = {Yamaguchi, Hiroyuki and Soda, Hiroshi and Nakamura, Yoichi and Takasu, Mineyo and Tomonaga, Nanae and Nakano, Hirofumi and Doi, Seiji and Nakatomi, Katsumi and Nagashima, Seiji and Takatani, Hiroshi and Fukuda, Minoru and Hayashi, Tomayoshi and Tsukamoto, Kazuhiro and Kohno, Shigeru},
 issue = {2},
 journal = {Cancer chemotherapy and pharmacology},
 month = {Feb},
 note = {PURPOSE: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefitinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment. METHODS: We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status </=3, age </=80 years, and stage IIIB-IV disease. In addition, EGFR mutations were analyzed in 24 patients. RESULTS: Multivariate analysis showed that favorable progression-free survival (PFS) after gefitinib treatment was associated with adenocarcinoma and high serum SP-D levels before treatment. EGFR mutation analysis of 24 patients showed that 16 patients had exon 19 deletion and/or exon 21 point mutations. EGFR mutations were significantly correlated with response to gefitinib and serum SP-D levels before treatment was significantly high in patients with the EGFR mutations. Serum SP-A levels were not associated with PFS. CONCLUSIONS: The present study showed that measurement of serum SP-D levels before treatment in patients with NSCLC may be a new surrogate marker for predicting the response to gefitinib., The original publication is available at www.springerlink.com, Cancer Chemotherapy and Pharmacology, 67(2), pp.331-338; 2011},
 pages = {331--338},
 title = {Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.},
 volume = {67},
 year = {2011}
}